New Insights into 4-Anilinoquinazolines as Inhibitors of Cardiac Troponin I-Interacting Kinase (TNNi3K)

Molecules. 2020 Apr 7;25(7):1697. doi: 10.3390/molecules25071697.

Abstract

We report the synthesis of several related 4-anilinoquinazolines as inhibitors of cardiac troponin I-interacting kinase (TNNi3K). These close structural analogs of 3-((6,7-dimethoxyquinazolin-4-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide (GSK114) provide new understanding of structure-activity relationships between the 4-anilinoquinazoline scaffold and TNNi3K inhibition. Through a small focused library of inhibitors, we observed that the N-methylbenzenesulfonamide was driving the potency in addition to the more traditional quinazoline hinge-binding motif. We also identified a compound devoid of TNNi3K kinase activity due to the addition of a methyl group in the hinge binding region. This compound could serve as a negative control in the study of TNNi3K biology. Small molecule crystal structures of several quinazolines have been solved, supporting observations made about overall conformation and TNNi3K inhibition.

Keywords: 4-anilino-quinazolines; cardiac troponin I–interacting kinase (TNNi3K); conformational flexibility; hinge binder; kinase inhibitor design.

MeSH terms

  • Aniline Compounds / pharmacology*
  • Humans
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Quinazolines / pharmacology*
  • Troponin I / metabolism

Substances

  • Aniline Compounds
  • Protein Kinase Inhibitors
  • Quinazolines
  • Troponin I
  • anilinoquinazoline
  • Protein Serine-Threonine Kinases
  • TNNI3K protein, human